24 results about "Viricidal activity" patented technology

The invention discloses a virulent bacteriophage vBValSR36H with a host being vibrio alginolyticus and application of the virulent bacteriophage vBValSR36H, and relates to the technical field of microbial control. The invention provides a bacteriophage capable of efficiently cracking Vibrio alginolyticus ATCC 17749T, the bacteriophage is named as vBValSR36H, the preservation number is 66248-B1, and the preservation address is Institute of Microbiology, Academy of Sciences in Guangdong Province. The vibrio alginolyticus bacteriophage vBValSR36H provided by the invention has good environmental stability and certain bactericidal activity, and has a relatively wide environmental adaptation range and relatively long survival time. The bacteriophage vBValSR36H provided by the invention can specifically and effectively kill, prevent and control related vibrio diseases, meanwhile, virulence factor genes and drug-resistant genes are not detected in the bacteriophage, and the bacteriophage vBValSR36H has the advantages of no toxic or side effect, high safety, environmental friendliness and wide application prospect. Therefore, the vibrio alginolyticus bacteriophage vBValSR36H can be completely applied to killing and / or preventing vibrio alginolyticus for non-disease diagnosis and treatment purposes.

The invention belongs to the technical field of biological medicines, and particularly relates to a granzyme B expression system as well as a preparation method and application thereof. According to the invention, granzyme B with bactericidal activity is screened out, a corresponding expression vector is designed by adopting circular RNA, a bacterium-specific ribosome binding site (RBS) is taken as a protein translation regulation and control element, and a Lipid nano-particle (LNP) is taken as a delivery vector, so that efficient delivery of the circular RNA for coding GZMB and specific expression of GZMB in bacteria are realized. According to the strategy, efficient delivery and specific expression of circRNA for coding GZMB in bacteria are achieved, and a safe and accurate scheme is provided for GZMB antibacterial treatment.

This invention relates to recombinant lyases and variants thereof, which have improved stability or bactericidal activity relative to the recombinant lyases. This application also relates to pharmaceutical compositions comprising the recombinant lyases and variants thereof, and their use for the prevention and / or treatment of bacterial infections (e.g., bacterial vaginosis).

The present application relates to a kind of pseudomonas aeruginosa engineering bacteria DUEC construction method and application.The DUEC engineering strain construction method of the present application is: response to kinase coding gene retS and sheath protein coding gene tssB2, tssB3 Knockout, H1-T6SS secretory effector protein Tse1-Tse4, Tse6-Tse8 catalytic site mutation, Tse5 Coding gene knockout.DUEC engineering strain can not only constitutively express and assemble H1-T6SS, but also can respond to adjacent sister cell source T6SS attack, assemble H1-T6SS at the position of being attacked.The present application constructs a series of effector protein combination inactivation mutant by gene knockout or catalytic site mutation method.Microscope observation and statistical analysis results show that no single effector protein is necessary for T6SS attack and assembly.By bacterial competition experiment, it is verified that all effector protein inactivation mutant 8eff c Lose T6SS + Vibrio cholerae and T6SS + Aeromonas dhaka's bactericidal activity, but 8eff c Can respond to T6SS physical attack, Tse6 N -Cre is specifically delivered to T6SS + In Vibrio cholerae.

The present application relates to the field of agricultural technology, and particularly relates to an amine group-containing alstoniascholaris alkaloid derivative, a preparation method and application thereof. The amine group-containing alstoniascholaris alkaloid derivative comprises a compound as shown in formula (I): wherein R comprises at least one of C3-C12 linear alkyl, C3-C12 branched alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C2-C6 aminoalkyl, tetrahydropyrrole group, piperidine group, piperidinylmethyl, N-methylpiperidine group and N-methylpiperidinylmethyl. The amine group-containing alstoniascholaris alkaloid derivative has good plant virus control and good fungicidal activity.

The application discloses a Pseudomonas aeruginosa single-stranded RNA bacteriophage and application thereof, and belongs to the technical field of bioengineering, wherein the Pseudomonas aeruginosa single-stranded RNA bacteriophage is named Pseudomonas aeruginosa phage Ppa61, is preserved in the China Center for Type Culture Collection, and has a preservation number of CCTCC No: M 20231334. The bacteriophage has strong bactericidal activity and a wide host spectrum on Pseudomonas aeruginosa, is specific to Pseudomonas aeruginosa, cannot kill other bacteria, and can be used alone or in combination with other substances, thereby providing a safe and non-toxic bacteriophage killing product for in-vivo and in-vitro Pseudomonas aeruginosa infection treatment, Pseudomonas aeruginosa disinfection and purification in aquaculture and other environments.

The invention provides an SP-1 polypeptide and application of a coding gene of the SP-1 polypeptide in inhibition of tight reaction and antibiosis, and belongs to the technical field of polypeptides. The amino acid sequence of the spider-derived SP-1 polypeptide is as shown in SEQ ID NO: 1. According to the present invention, the SP-1 polypeptide can specifically inhibit Escherichia coli and pseudomonas aeruginosa tight reaction key small molecule (p) ppGpp synthase activity, strong antibacterial activity is represented, and the MIC of the SP-1 polypeptide on Escherichia coli and pseudomonas aeruginosa is 2.4 [mu] M and 1.5 [mu] M respectively, and is significantly lower than the MIC (14.5 [mu] M and 12.3 [mu] M) of kanamycin of a positive control group under the same experiment condition; in addition, the SP-I peptide shows efficient bactericidal activity, the minimum bactericidal concentration of the SP-I peptide to escherichia coli and pseudomonas aeruginosa is 2.0 mu M, and the SP-I peptide can effectively inhibit generation of escherichia coli and pseudomonas aeruginosa biological membranes. Therefore, the SP-1 polypeptide can be used as an active ingredient to be applied to preparation of antibacterial drugs for inhibiting multidrug resistance bacteria.

The application discloses application of mulberroside D in synergistic polymyxin antibacterial activity, and belongs to the technical field of medicines, and particularly relates to application of mulberroside D in synergistic polymyxin antibacterial activity. The application discloses application of mulberroside D in preparation of a product for enhancing antibacterial activity and / or bactericidal activity of an antibacterial drug. The mulberroside D can effectively synergize in-vivo and in-vitro antibacterial activity of polymyxin on multi-drug resistant bacteria, can produce synergistic antibacterial effect, and provides a new treatment strategy for clinical treatment of bacterial infectious diseases.

The invention relates to a group of polypeptides with rapid bactericidal activity and application thereof, and the polypeptides are amphiphilic polypeptides and have a cation alpha-helical structure. The polypeptide specifically comprises a C22-01 polypeptide, a C22-02 polypeptide, a C22-03 polypeptide, a C22-04 polypeptide and a C22-05 polypeptide, wherein the sequence of the C22-01 polypeptide is shown as SEQ ID NO.1, the sequence of the C22-02 polypeptide is shown as SEQ ID NO.2, the sequence of the C22-04 polypeptide is shown as SEQ ID NO.3, the sequence of the C22-05 polypeptide is shown as SEQ ID NO.4, and the sequence of the C22-05 polypeptide is shown as SEQ ID NO.5. The carboxyl terminals of the polypeptides are subjected to amidation (-NH2) modification.

This invention relates to a novel natural microbial metabolite: Fcl-8, derived from the fermentation broth of *Xenorhabdus budapestensis* XBD8. Purified Fcl-8 is a snow-white, flocculent crystal, highly soluble in water, as shown in Figure 1. The chemical structural formula of Fcl-8 is shown in Figure 2, with the chemical formula C1. 57 H 102 N 14 O 12 With a molecular weight of 1175.78744, its typical secondary mass spectrometry information is shown in Figure 3. Fcl-8 is derived from a natural microbial metabolite, has a novel structure and high biological activity, and possesses great potential for development into a novel biopesticide.

The invention discloses a vibrio cantoniensis phage VCP13AVCGD9 as well as a composition and application of the vibrio cantoniensis phage VCP13AVCGD9, the vibrio cantoniensis phage VCP13AVCGD9 is preserved in Guangdong Microbiological Culture Collection Center on November 24, 2025, the preservation number of the vibrio cantoniensis phage VCP13AVCGD9 is GDMCC NO. 67344-B1, and the vibrio cantoniensis phage VCP13AVCGD9 is classified and named as Vibrio campbelli phage VCP13AVCGD9. The vibrio canetinii bacteriophage VCP13AVCGD9 provided by the invention has good acid-base stability, can still keep relatively high titer after being treated for 96 hours under the condition that the pH value is 4.0-8.0, is beneficial to continuously keeping bactericidal activity in a culture water body, and acts on vibrio canetinii in animal gastrointestinal tracts in a targeting manner.

The invention discloses an engineered PVC protein compound for targeted removal of intracellular staphylococcus aureus as well as a preparation method and application of the engineered PVC protein compound, and belongs to the fields of genetic engineering, microbiology and drug delivery. Genetic engineering modification is carried out on PVC, a natural recognition domain of tail fiber protein of the PVC is replaced by a staphylococcus aureus receptor binding structural domain (SRapid BR), and meanwhile, natural toxin protein loaded in an inner cavity of the PVC is replaced by human beta-defensin-3 (HBD-3) with efficient bactericidal activity. The engineered compound can directly deliver HBD-3 into infected cells, effectively remove intracellular staphylococcus aureus which is difficult to kill by conventional antibiotics, and relieve inflammatory response caused by infection. The invention provides a brand-new treatment strategy for resisting intracellular bacterial infection with high targeting, and shows a wide application prospect as a programmable protein delivery platform.

The present application relates to the technical field of antibacterial drugs, in particular to a small-molecule antibacterial polypeptide, a preparation method and uses thereof. The antibacterial peptide provided by the present application has stronger bacteriostatic activity than most other derivative polypeptides and antibacterial polypeptides disclosed in existing reports. The bactericidal activity evaluation was carried out using a plurality of strains known to have drug resistance, and the results showed that the antibacterial peptide provided by the present application has broad-spectrum bacteriostatic activity on drug-resistant strains, the bacteriostatic effect is more comprehensive, and the indications are more extensive.

The present application relates to the technical field of antibacterial drugs, in particular to a small-molecule antibacterial polypeptide, a preparation method and uses thereof. The antibacterial peptide provided by the present application has stronger bacteriostatic activity than most other derivative polypeptides and antibacterial polypeptides disclosed in existing reports. The bactericidal activity evaluation was carried out using a plurality of strains known to have drug resistance, and the results showed that the antibacterial peptide provided by the present application has broad-spectrum bacteriostatic activity on drug-resistant strains, the bacteriostatic effect is more comprehensive, and the indications are more extensive.

The invention discloses a salmonella paratyphi targeting antibacterial peptide as well as a preparation method and application thereof, and belongs to the field of bioengineering, and the sequence of the antibacterial peptide is as shown in SEQ ID No.1; the invention further discloses application of the antibacterial peptide targeting the salmonella paratyphi to preparation of a medicine for treating salmonella paratyphi infectious diseases. The antibacterial peptide disclosed by the invention has efficient targeted bactericidal activity on salmonella paratyphi, and has no toxicity on human red blood cells, so that the antibacterial peptide has the potential of becoming a feed antibiotic substitute.

The present invention relates to an asymmetric aromatic diselenide compound and the use thereof in the preparation of pesticides, particularly to the use thereof in the preparation of anti-plant virus agents and fungicides. The asymmetric aromatic diselenide compound of the present invention exhibits a good efficiency on tobacco mosaic virus (TMV) at a concentration of 500 mg / L, achieving an in-vivo inactivation efficiency of 71.6%, an in-vivo protective efficiency of 58.3%, and an in-vivo therapeutic efficiency of 60.1%. The asymmetric aromatic diselenide compound of the present invention exhibits good control effects on tomato early blight, wheat Fusarium head blight, rice blast, pepper Phytophthora blight, rapeseed Sclerotinia rot, cucumber gray mold, rice sheath blight, cucumber wilt, peanut brown spot, apple ring rot, wheat sharp eyespot, southern corn leaf blight, watermelon anthracnose, and rice bakanae disease at a concentration of 50 mg / L, and has a fungicidal activity of up to 92.3%.

The invention discloses a vibrio parahaemolyticus recombinant outer membrane protein OmpU and application thereof.The recombinant protein is the vibrio parahaemolyticus outer membrane protein OmpU, the amino acid sequence of the recombinant protein is shown as SEQ ID NO: 1 or is a variant which has at least 90% identity with SEQ ID NO: 1 and retains immunoprotectiveness, and the protein has high surface exposure, high expression abundance and strong immunogenicity; the generation of a high-titer antibody can be induced and complement-dependent bactericidal activity can be mediated. Experiments show that the protein is highly conservative in vibrio parahaemolyticus and other vibrios, and can be used as a broad-spectrum subunit vaccine, a diagnostic reagent or a candidate antigen of a therapeutic antibody.

The application provides a use of Derazantinib, CAS No. 1234356-69-4, for preparing an anti-Gram-positive bacterial infection drug. The technical scheme of the application discloses a new medical use of Derazantinib. The technical scheme of the application discloses a new medical use of Derazantinib. Derazantinib shows better antibacterial activity on Staphylococcus aureus, can significantly inhibit the formation of a biofilm, and can penetrate a mature biofilm to effectively kill bacteria in the mature biofilm. Derazantinib shows more significant bactericidal activity than vancomycin. In addition, Derazantinib shows strong inhibitory effect on MRSA, MSSA, Enterococcus faecalis and other clinically drug-resistant bacteria.

This invention relates to the field of agricultural technology, and more particularly to cypermethrin derivatives containing an acylhydrazone structure, their preparation methods, and applications. Cypermethrin derivatives containing an acylhydrazone structure include those with the structural formula shown in formula (I): wherein, R... 1 Including at least one of alkyl, phenyl, furanyl, pyridyl, indoleyl and cycloalkyl, R 2 Including at least one of hydrogen, methyl, and ethyl; or, R 1 and R 2 The combined derivatives of white vine alkaloids containing acylhydrazone structures exhibit good activity in preventing and controlling plant viruses and in killing bacteria.

A composition comprising active ingredient a and active ingredient b, wherein active ingredient a is a compound of the general formula A, and active ingredient b is at least one compound having insecticidal, acaricidal or fungicidal activity which is different from the compound of the general formula A. The composition has the advantages of synergism, broadened spectrum of control, etc. and can be used for controlling various pests (especially mites) and plant diseases caused by various fungi, bacteria, nematodes, viruses.

The invention provides an application of PFM01 in preparation of a medicine for resisting gram-positive bacterial infection, and the CAS number of the PFM01 is 1558598-41-6. According to the technical scheme, the novel medical application of PFM01 is disclosed, the PFM01 has good antibacterial activity and anti-biofilm activity on various gram-positive bacteria, can inhibit growth of staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, enterococcus faecium and the like, especially has an obvious inhibiting effect on methicillin-resistant staphylococcus aureus (MRSA), and can be used for preparing the medicine for preventing and treating the diseases such as the staphylococcus aureus, the staphylococcus epidermidis, the enterococcus faecalis, the enterococcus faecium and the like. And compared with vancomycin, the vancomycin compound shows more obvious bactericidal activity, and can obviously inhibit the formation of a biofilm and kill bacteria in the formed biofilm.

The present invention relates to a recombinant lyase and a variant thereof. The variant has improved stability or bactericidal activity relative to the recombinant lyase. The present invention also relates to a pharmaceutical composition comprising the recombinant lyase and the variant thereof, and a use thereof in preventing and treating bacterial infections.

The invention discloses an application of epothilone and rifampicin in preparation of a synergistic anti-tuberculosis drug, and belongs to the technical field of anti-tuberculosis drugs. The core of the application is that the epothilone and the rifampicin are combined for use, and through the synergistic effect of the epothilone and the rifampicin, the bactericidal activity of the rifampicin is remarkably enhanced, the minimum inhibitory concentration of the rifampicin is reduced, and development of drug resistance of mycobacterium tuberculosis is effectively inhibited. The invention also provides a pharmaceutical preparation and a medicine box containing the two active components. According to the combined application scheme, the clinical dosage of rifampicin can be reduced, so that adverse reactions such as hepatotoxicity of the rifampicin are reduced, and the compound is suitable for treating sensitive and rifampicin-resistant tuberculosis and has important clinical value and application prospects.

A composition and use thereof. The composition comprises an active component a and an active component b; the active component a is a compound as shown in general formula A; and the active component b is at least one of compounds which have insecticidal, acaricidal or bactericidal activity and are different from the compound as shown in general formula A. The composition has the advantages of synergistic effect and expanding prevention and treatment spectrum, and can be used for preventing and treating various pests, particularly mite damage, and plant diseases caused by various fungi, bacteria, nematodes and viruses.